Navigation Links
New Findings in Fragile X Mental Retardation Protein

Researchers in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine have done crucial progress in understanding Fragile X mental retardation protein (FMRP), laying the groundwork for possible new treatments for Fragile X syndrome(FXS).

Fragile X syndrome, the leading inherited form of mental retardation is mainly caused by a mutation in the FMR1 gene on the X chromosome, leading to the loss of FMRP, which is abundantly expressed in the brain and testes. Without this protein, brain development is hampered and nerve cells cannot communicate with each other appropriately, resulting in the reduced ability to learn and memorize.

Fragile X syndrome affects about one in 4,000 males and one in 8,000 females. About 20 percent of children with FXS have autism and about five percent of autistic children have FXS. The research team led by Yingqun Huang, M.D., assistant professor in Yale Ob/Gyn, previously found that FMRP interacts with a nuclear mRNA export protein NXF2, in the mouse brain and testes. In this study, the team used mouse neuronal cells to explore the functional characteristics of this interaction.

We found that FMRP, together with NXF2, acts to down-regulate the expression of its target, the messenger RNA that encodes NXF1, which is an essential protein needed to transport most mRNAs from the nucleus to the cytoplasm of cells, said Huang. Our findings explain why the NXF1 protein level is much lower in the hippocampal neurons involved in learning and memory than in many other cells. This may suggest that a high level of NXF1 might hinder the function of these cells.

We are one of the first two labs to show that FMRP regulates gene expression at the mRNA stability level, Huang added. The idea is to find the mechanisms underlying the function of FMRP so in the future, we can develop more effective interventions.

Huang said future studies will look more clo sely at how FMRP works with NXF2 to regulate its targets. She said, We expect to identify more targets which are regulated by FMRP and NXF2. This will be a new direction in the FMRP research field.


'"/>




Related medicine news :

1. Latest Findings On The Deadly Disease - SARS
2. New Findings Could Reduce The Extent Of Spinal Cord Injuries
3. New Findings for Repeated Miscarriages
4. How Healthy Are Herbal Products? US Findings.
5. Dispute in Findings about Radiation exposure
6. New Findings on Autism Research
7. Engineering Nutrient-Rich Plants Made For Feasible By New Findings
8. Study Findings Could Help In Developing A Better Drug Delivery System
9. Findings Suggest New Method to Fight Staph Infections
10. Most Suicide Rates Decline, but Findings Are Puzzling
11. Arimidex-Herceptin Combo Therapy For Breast Cancer-Clinical Trial Findings
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/18/2017)... ... February 17, 2017 , ... Focused ... innovation in the industry, according to the recent NEJM Catalyst Insights Report on ... of the NEJM Catalyst Insights Council, a qualified group of U.S. executives, clinical ...
(Date:2/18/2017)... ... 2017 , ... A new directory from the Senior Veterans ... connect elderly veterans of America's armed forces to a range of senior care ... on this year's increase in the Veterans Pension with Aid & Attendance for ...
(Date:2/17/2017)... ... 2017 , ... For the first time, International Scholarship and ... floor for the 2017 HIMSS Conference & Exhibition at the Orange ... than 40,000 healthcare industry professionals are expected at the conference, where they will ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today ... Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will ... used electronic patient signatures solution in healthcare . , Since it first ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer diagnostics workflow solution provider ... 20 – 22 in San Francisco. As part of the Tri-Conference expo, which ... workflow solution, as well as its new precision medicine platform, “Crosswalk Insight: Oncology™.” ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for ... Vincent J. Angotti has been appointed ... company,s board of directors, effective Monday, March 6, ... experience leading executive and commercial teams at public ...
(Date:2/16/2017)... , Feb. 16, 2017  Prescription pain medications ... department visit are necessary for long-term opioid use to ... Feb. 16 th edition of The New ... "Emergency physicians see more patients in acute pain than ... Parker , MD, FACEP, president of the American College ...
(Date:2/16/2017)... Research and Markets has announced the addition of the ... Function, Application, Cancer Type, Technology - Forecast to 2025" report ... ... grow at a CAGR of around 28.6% over the next decade ... Some of the prominent trends that the market is witnessing include ...
Breaking Medicine Technology: